UQION Tablet

 

Ubidecarenone (Co-enzyme Q10) 300 mg

​

PRESCRIBING INFORMATION

1. Name of the Product

UQION Tablet

 

2. Composition

Each film-coated tablet contains:
Ubidecarenone (Co-enzyme Q10) 300 mg
Excipients q.s.

 

3. Dosage Form

Film-coated tablet

​

4. Pharmacological Properties

Ubidecarenone (Co-enzyme Q10) is a lipid-soluble quinone naturally present in mitochondrial membranes. It functions as:

 

4.1 Mechanism of Action

• A key component of the electron transport chain

• Essential for ATP synthesis

• A potent antioxidant, protecting cellular membranes from oxidative damage

• A stabilizer of mitochondrial membrane integrity

It plays a critical role in tissues with high energy demand, including the heart, skeletal muscle, brain, and immune cells.

 

4.2 Pharmacodynamic Properties

• Facilitates mitochondrial oxidative phosphorylation

• Reduces reactive oxygen species (ROS)

• Supports cellular energy metabolism

• Helps maintain membrane phospholipid stability

Deficiency or depletion may occur in chronic illness, aging, statin therapy, and conditions associated with increased oxidative stress.

 

4.3 Pharmacokinetic Properties

• Absorbed from the small intestine (lipid-dependent absorption)

• Peak plasma concentrations achieved within 5–10 hours

• Distributed widely in tissues, especially heart and liver

• Metabolized primarily in the liver

• Eliminated via biliary excretion

Bioavailability improves when administered after meals.

 

5. Indications

UQION Tablet is indicated as adjunctive nutritional support in:

 

Cardiovascular Conditions

• Congestive heart failure (supportive therapy)

• Ischemic heart disease

• Hypertension

• Statin-associated myopathy

 

Fatigue & Low Energy States

• Chronic fatigue

• Age-related fatigue

• General weakness and asthenia

• Cancer-related fatigue (supportive care)

 

Neurological Conditions (Supportive)

• Migraine prophylaxis

• Neurodegenerative disorders (adjunct use)

 

Metabolic Disorders

• Type 2 diabetes mellitus (adjunct)

• Diabetic neuropathy

• Metabolic syndrome

 

Fertility Support

• Male infertility (improves sperm motility parameters)

• Female infertility (oocyte mitochondrial support)

 

Oncology Supportive Care

• During chemotherapy and radiotherapy (to support cellular energy and antioxidant status)

• Post-therapy recovery

• Patients experiencing treatment-related fatigue

 

UQION is not an anti-cancer medication and should not replace standard oncological therapy.

 

6. Dosage and Administration

Adults:
One tablet (300 mg) once daily after food, or as directed by the physician.

Duration of therapy depends on clinical condition.

 

7. Contraindications

• Known hypersensitivity to Co-enzyme Q10 or any component of the formulation.

 

8. Warnings and Precautions

• Use with caution in patients receiving anticoagulants (e.g., warfarin); monitor INR.

• Not intended to replace conventional therapy in serious illnesses.

• Safety in pregnancy and lactation has not been fully established; use only if advised by a physician.

• Keep out of reach of children.

 

9. Drug Interactions

• May reduce anticoagulant effect of warfarin.

• Concomitant antihypertensive therapy may require monitoring.

• Statins may reduce endogenous CoQ10 levels.

 

10. Adverse Effects

Co-enzyme Q10 is generally well tolerated.

Reported adverse effects are mild and may include:

• Gastrointestinal discomfort

• Nausea

• Headache

• Insomnia (rare)

 

11. Overdosage

No serious toxicity reported at recommended doses.
In case of accidental overdose, symptomatic treatment is advised.

 

12. Storage

Store in a cool, dry place below 25°C.
Protect from light and moisture.

 

13. Presentation

Available as strip of 15 tablets.